A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers

Annals of Oncology

Volumn 27, Issue 6, 2016, Pages 1116-1122

  Chi, K N ^a,b   Yu, E Y ^c   Jacobs, C ^d   Bazov, J ^b   Kollmannsberger, C ^a   Higano, C S ^c   Mukherjee, S D ^e   Gleave, M E ^b   Stewart, P S ^d   Hotte, S J ^e  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF WASHINGTON   (United States)

^d OncoGenex Pharmaceuticals   (United States)

^e JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Antisense oligonucleotide; Apatorsen; Heat shock protein 27; OGX 427; Phase I clinical trial; Solid tumors

Indexed keywords

APATORSEN; CREATININE; HEAT SHOCK PROTEIN 27; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; ANTISENSE OLIGONUCLEOTIDE; DIAZEPAM; HSPB1 PROTEIN, HUMAN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BLADDER CANCER; BRAIN HEMORRHAGE; BRAIN METASTASIS; BREAST CANCER; CASTRATION RESISTANT PROSTATE CANCER; CHILL; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE RELEASE SYNDROME; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FLUSHING; HEADACHE; HEMATURIA; HOT FLUSH; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERHIDROSIS; HYPERTENSION; HYPOKALEMIA; INFUSION RELATED REACTION; LOADING DRUG DOSE; LUNG CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OVARY CANCER; OXYGEN SATURATION; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTHROMBIN TIME; PRURITUS; QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; URTICARIA; VOMITING; ADVERSE DRUG REACTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP27 HEAT-SHOCK PROTEINS; HUMANS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84974845947     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw068     Document Type: Article

References (25)

1. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005; 10: 86-103.
2. Bruey JM, Paul C, Fromentin A et al. Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. Oncogene 2000; 19: 4855-4863.
3. Concannon CG, Orrenius S, Samali A. Hsp27 inhibits cytochrome c-mediated caspase activation by sequestering both pro-caspase-3 and cytochrome c. Gene Expr 2001; 9: 195-201.
4. Charette SJ, Landry J. The interaction of HSP27 with Daxx identifies a potential regulatory role of HSP27 in Fas-induced apoptosis. Ann N Y Acad Sci 2000; 926: 126-131.
5. Garrido C, Ottavi P, Fromentin A et al. HSP27 as a mediator of confluencedependent resistance to cell death induced by anticancer drugs. Cancer Res 1997; 57: 2661-2667.
6. Rogalla T, Ehrnsperger M, Preville X et al. Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. J Biol Chem 1999; 274: 18947-18956.
7. Wyttenbach A, Sauvageot O, Carmichael J et al. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum Mol Genet 2002; 11: 1137-1151.
8. Garrido C, Schmitt E, Cande C et al. HSP27 and HSP70: potentially oncogenic apoptosis inhibitors. Cell Cycle 2003; 2: 579-584.
9. Lavoie JN, Hickey E, Weber LA, Landry J. Modulation of actin microfilament dynamics and fluid phase pinocytosis by phosphorylation of heat shock protein 27. J Biol Chem 1993; 268: 24210-24214.
10. Rane MJ, Pan Y, Singh S et al. Heat shock protein 27 controls apoptosis by regulating Akt activation. J Biol Chem 2003; 278: 27828-27835.
11. Zoubeidi A, Zardan A, Beraldi E et al. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 2007; 67: 10455-10465.
12. Shiota M, Bishop JL, Nip KM et al. Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Res 2013; 73: 3109-3119.
13. Rocchi P, Beraldi E, Ettinger S et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 2005; 65: 11083-11093.
14. Gibert B, Eckel B, Gonin V et al. Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo. Br J Cancer 2012; 107: 63-70.
15. Rocchi P, So A, Kojima S et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004; 64: 6595-6602.
16. Kuramitsu Y, Wang Y, Taba K et al. Heat-shock protein 27 plays the key role in gemcitabine-resistance of pancreatic cancer cells. Anticancer Res 2012; 32: 2295-2299.
17. Kamada M, So A, Muramaki M et al. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther 2007; 6: 299-308.
18. Hsu HS, Lin JH, Huang WC et al. Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27. Cancer 2011; 117: 1516-1528.
19. Hummel J, McKendrick S, Brindley C, French R. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat 2009; 8: 38-49.
20. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
21. Chi KN, Eisenhauer E, Fazli L et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005; 97: 1287-1296.
22. Henry SP, Geary RS, Yu R, Levin AA. Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Curr Opin Investig Drugs 2001; 2: 1444-1449.
23. Weiner GJ, Liu HM, Wooldridge JE et al. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997; 94: 10833-10837.
24. Galbraith WM, Hobson WC, Giclas PC et al. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 1994; 4: 201-206.
25. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Canc Res 2008; 14: 6302-6309.